东菱克栓酶治疗慢性肺源性心脏病急性加重期的临床及预后的观察

目的探讨东菱克栓酶(DF-521)对慢性肺源性心脏病急性加重期的疗效。方法245例慢性肺源性心脏病急性加重期的患者随机分为治疗组和常规组。两组患者均给以常规抗感染、祛痰、解痉、纠正水电解质紊乱、低流量吸氧抗心衰等综合治疗。治疗组再加用东菱克栓酶,观察治疗前后的临床疗效及实验室检查、并发症,并随后观察治疗后12周内患者的心、脑血管事件发生情况,再次入院次数等。结果治疗组总有效率(93%)大于对照组(75%),(P<0.05);实验室检查治疗前后常规组无统计学差异,而治疗组明显好转(P<0.05)。常规组并发脑梗塞(7/124)明显高于治疗组(1/124)(P<0.05)。结论东菱克栓酶对慢性肺心病急性发作期患者的临床症状、实验室检查及血气分析改善均有良好的效果,可作为慢性肺源性心脏病急性加重期的常规治疗方法之一。

Efficacy of Batroxobin (DF-521) in the Treatment of the Cor Pulmonale in Acute Exacerbation Phase

Objective To evaluate the efficacy of batroxobin (DF-521) in the treatment of cor pulmonale in acute exacerbation phase. Methods 245 patients with cor pulmonale in acute exacerbation phase were divided randomly into study group (124 cases) and control group (121 cases). All the patients in these two groups were given the same routine treatments such as anti-infection, expectorant, relieving spasm, balancing hydro-electrolytic disorder, low flow oxygen inhalation, and conventional digitals, diuretics, vasodilators therapy. In addition to these treatments, patients in the study group were given with batroxobin (DF-521). The clinical features and laboratory tests in these two groups were compared before and after the treatment. The treated patients were monitored for 12 weeks for the clinical effect, major adverse events rate, complication, and stroke. Results Both clinical features and the results of laboratory tests in the study group were markedly improved after the treatment (93% vs 75%)(P<0.05). In the control group, not only the number of hospitalization was increased, but also the time between readmission was shorter (P<0.05). Frequency of brain stroke in control group (7/124) was higher than those in the study group (1/121)(P<0.05). Conclusion Batroxobin (DF-521) was effective in the treatment of the cor pulmonale in acute exacerbation phase.